Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy
March 4th, 2021 by Liguo Wang
Nature Chemical Biology, Published online: 04 March 2021; doi:10.1038/s41589-021-00742-5
A selective and potent CDK2 degrader was developed that induced differentiation of acute myeloid leukemia cell lines and primary patient cells.